[Treatment of intermediate and high grade non-Hodgkin's lymphoma].

Abstract

Since the study by SWOG in 1993, CHOP regimen has been the standard therapy for patients with advanced stage intermediate-grade or high-grade non-Hodgkin's lymphoma. Three-year estimated survival for all patients was about 50%. However, five-year disease free survival of the patients with high or high-intermediate risk by age-adjusted international prognostic index(IPI) is less than 30%. For the patients with low and low-intermediate IPI, high cure rate can be achieved by CHOP, or modified CHOP therapy. For the patients in high or high-intermediate risk groups, the CHOP regimen is not satisfactory. High-dose chemotherapy with haematopoietic stem cell rescue has been tried for those patients. We are conducting pilot study of high-dose chemotherapy with peripheral blood stem cell transplant(PBSCT) following induction with double CHOP regimen. Although the results are encouraging, confirmation with randomized prospective trials are necessary.

• Authors: T Yamazaki, Y Kura, U Sawada
• Journal: Nihon rinsho. Japanese journal of clinical medicine (Nihon Rinsho) Vol. 58 Issue 3 Pg. 695-8 (Mar 2000) ISSN: 0047-1852 [Print] Japan
• PMID: 10741148 (Publication Type: English Abstract, Journal Article, Review)

Chemical References

• Vincristine
• Doxorubicin
• Cyclophosphamide
• Prednisolone

Topics

• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Combined Modality Therapy
• Cyclophosphamide (administration & dosage)
• Doxorubicin (administration & dosage)
• Hematopoietic Stem Cell Transplantation
• Humans
• Lymphoma, Non-Hodgkin (pathology, therapy)
• Neoplasm Staging
• Prednisolone (administration & dosage)
• Prognosis
• Risk
• Vincristine (administration & dosage)